27 completed, 8 unknown, 7 recruiting, 4 terminated. 52 Phase 2, 21 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 52 | Completed 27, Unknown 8, Recruiting 7, Terminated 4, Withdrawn 4, Active not recruiting 2 |
| Phase 1 | 21 | Completed 8, Unknown 6, Recruiting 5, Withdrawn 2 |
Follow Acute Lymphocytic Leukemia: new trials by email Literature Review of Acute Lymphocytic Leukemia trials Research Report on Acute Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood Haplo-Identical / Cord Blood Transplant - aGVHD, Acute Myelogenous Leukemia | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 36 | 2025-08-13 | 2026-09-15 |
| BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL CAR19TIF cells, Fludarabine, Cyclophosphamide - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2025-06-20 | 2025-06-25 |
| TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2025-02-15 | 2026-05-08 |
| A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies Fludarabine + Total Marrow Irradiation - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Naoyuki G. Saito, M.D., Ph.D. | 2023-10-01 | 2023-12-11 | |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-26 |
| Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy Inotuzumab ozogamicin - Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 31 | 2022-10-18 | 2026-04-16 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 22 | 2019-01-02 | 2026-01-06 |
| Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia Inotuzumab Ozogamicin - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Leland Metheny | 44 | 2017-07-31 | 2026-09-10 |
| A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies Drugs and anti-CD19 CAR transduced T cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Guangzhou Medical University | 100 | 2017-06-30 | 2017-06-20 |
| Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies Fludarabine, Cyclophosphamide, Mesna - B-Lymphoid Malignancies, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 49 | 2017-06-21 | 2024-03-25 |
| StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies Unmanipulated UCB, SR-1 UCB - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2017-04-01 | 2017-12-05 | |
| Allo HSCT Using RIC for Hematological Diseases Allopurinol, Fludarabine, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 156 | 2017-03-09 | 2023-09-21 |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Cyclophosphamide, Tacrolimus, Mycophenolate mofetil - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Terminated | Loyola University | 5 | 2017-01-18 | 2024-07-10 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-10-25 |
| PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma anti-CD19 CAR-NK cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-09-01 | 2016-12-06 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-07-01 | 2016-08-01 |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies Drugs and Anti-CD19-CAR transduced T cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Shenzhen Institute for Innovation and Translational Medicine | 28 | 2016-01-15 | 2021-03-19 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis mycophenolate mofetil, Sargramostim, Filgrastim - Hodgkin's Lymphoma, Lymphoid Leukemia | Phase 2 | Completed | Virginia Commonwealth University | 31 | 2015-11-04 | 2023-01-23 |
Showing 20 of 52. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (52) · Leukemia, Myeloid, Acute (32) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (23) · Leukemia, Lymphocytic, Chronic, B-Cell (22) · Myelodysplastic Syndromes (22) · Lymphoma, Non-Hodgkin (17) · Leukemia (13) · Lymphoma (11) · Multiple Myeloma (11) · Anemia, Refractory, with Excess of Blasts (9) · Hodgkin Disease (9) · Lymphoma, Follicular (8) · Lymphoma, Mantle-Cell (8) · Burkitt Lymphoma (7) · Lymphoma, B-Cell, Marginal Zone (6)
Hemic and Lymphatic Diseases (52) · Immune System Diseases (52) · Immunoproliferative Disorders (52) · Lymphatic Diseases (52) · Neoplasms by Histologic Type (52) · Hematologic Diseases (51) · Leukemia, Lymphoid (51) · Lymphoproliferative Disorders (51) · Neoplasms (51) · Leukemia (39) · Pathologic Processes (34) · Pathological Conditions, Signs and Symptoms (34) · Chronic Disease (33) · Disease Attributes (33) · Bone Marrow Diseases (31)
Cyclophosphamide (17) · fludarabine (14) · fludarabine phosphate (9) · Mycophenolic Acid (8) · Tacrolimus (8) · Whole-Body Irradiation (8) · Granulocyte Colony-Stimulating Factor (6) · Methotrexate (6) · Busulfan (5) · Melphalan (5) · Cytarabine (4) · Filgrastim (4) · Antigens, CD19 (3) · Inotuzumab Ozogamicin (3) · Sensitivity and Specificity (3)
Masonic Cancer Center, University of Minnesota (6) · M.D. Anderson Cancer Center (4) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · Chinese PLA General Hospital (2) · National Cancer Institute (NCI) (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Novartis Pharmaceuticals (2) · Assistance Publique - Hôpitaux de Paris (1) · Callisto Pharmaceuticals (1) · Case Comprehensive Cancer Center (1) · Colorado Blood Cancer Institute (1) · Delta-Fly Pharma, Inc. (1) · Hospices Civils de Lyon (1) · Incyte Biosciences International Sàrl (1) · Indiana University (1)
United States (40) · China (8) · France (3) · Belgium (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Leland Metheny, MD (2) · A. John Barrett, M.D. (1) · Amir A Toor, MD (1) · Barton Kamen, MD (1) · Brandon Triplett, MD (1) · Bruno Carneiro de Medeiros (1) · Christopher G Kanakry, M.D. (1) · Claudio Brunstein, MD, PhD (1) · Claudio G. Brunstein, MD, PhD (1) · Dolores Grosso, DNP, CRNP (1) · Erica Warlick, MD (1) · Farhad Ravandi-Kashani, M.D. (1) · Gary Jacob, PhD (1) · Gregory Bociek, MD (1)
PMID 23524640, PMID 12011123, PMID 18997171, PMID 19706886, PMID 21684344, PMID 22133778, PMID 22422826, PMID 23065508, PMID 25682597, PMID 28054442, PMID 29248669, PMID 29296758, PMID 30389035, PMID 30668890, PMID 32023374, PMID 33231879, PMID 34515338, PMID 35622074, PMID 38170741, PMID 38238616, PMID 39670843, PMID 41671463
2018 (1), 2023 (1), P30CA072720 (1)